Crohn’s disease drugmakers to benefit from expected rise in cases



NSA Digital Archive/iStock via Getty Images

Pharmaceutical companies that market drugs for Crohn’s disease — or have ones in development — are poised to benefit from an expected rise in cases of the inflammatory bowel disease.

As of 2022, there were 1.63M cases of Crohn’s in eight

Source link

Leave A Reply

Your email address will not be published.